Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for ...

The U.S. Food and Drug Administration approved a new prescription-strength pain reliever from Vertex Pharmaceuticals on Jan. 30, 2025. Journavx is a non-opioid drug that prevents peripheral nerves ...

There are so many things to love about Costco. The wholesale giant has become one of the world's largest retailers, achieving ...

BOSTON, January 12, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the ...

--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced an exclusive collaboration and license agreement for the ...

Vertex has been running a number of trials because if there’s one thing that we can take away from the failed drug development projects of the past, it’s that there are many kinds of pain.

Get Wall Street's Hottest Chart Every Morning RBC Capital Markets says Vertex management is optimistic about the recently approved Alyftrek. They predict that most of the 6,000 patients who ...

We're kicking off the 43rd Annual Healthcare Conference this morning, and I couldn't be more delighted to introduce Vertex's CEO, Reshma Kewalramani. She's going to come on stage to give a ...

UnitedHealthcare likely to cover Vertex’s pain drug Vertex Pharmaceuticals received FDA approval for a new non-opioid pain drug, marketed as Journavx, and it appears the nation’s largest ...

Get prepared with the key expectations. Vertex Pharmaceuticals (NASDAQ: VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and this platform has helped ...

We earn commissions from purchases you make using links in our articles. Learn more. A vise will make an amazingly versatile addition to your workbench. Who among us hasn’t wished for a second ...